These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8484985)

  • 1. Towards an international register of cancer trials: the UKCCCR register of U.K. trials.
    Fayers PM; Armitage T
    Eur J Cancer; 1993; 29A(6):907-12. PubMed ID: 8484985
    [No Abstract]   [Full Text] [Related]  

  • 2. UKCCCR Register of U.K. Cancer Trials.
    Fayers P; Gibson D; Mossman J
    Control Clin Trials; 1995 Jun; 16(3):172-81. PubMed ID: 7796599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The UKCCCR Register of UK Cancer Trials.
    Fayers PM
    Clin Oncol (R Coll Radiol); 1995; 7(2):72-6. PubMed ID: 7619767
    [No Abstract]   [Full Text] [Related]  

  • 4. Trends in UK cancer trials: results from the UK Coordinating Committee for Cancer Research National Register of Cancer Trials.
    Vale C; Stewart L; Tierney J;
    Br J Cancer; 2005 Mar; 92(5):811-4. PubMed ID: 15756251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. United Kingdom Cancer Research Campaign approach to quality-of-life research in cancer clinical trials.
    Hopwood P
    J Natl Cancer Inst Monogr; 1996; (20):103-5. PubMed ID: 8750479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Civilian Health and Medical Program of the Uniformed Services (CHAMPUS)/ TRICARE; coverage of phase II and phase III clinical trials sponsored by the National Institutes of Health National Cancer Institute. Final rule.
    Office of the Secretary, DoD
    Fed Regist; 2006 Jun; 71(118):35389-91. PubMed ID: 16795948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Representation of older patients in cancer treatment trials.
    Trimble EL; Carter CL; Cain D; Freidlin B; Ungerleider RS; Friedman MA
    Cancer; 1994 Oct; 74(7 Suppl):2208-14. PubMed ID: 8087794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Sufficient life expectancy": an amazing inclusion criterion in cancer phase II-III trials.
    Penel N; Clisant S; Lefebvre JL; Adenis A
    J Clin Oncol; 2009 Sep; 27(26):e105. PubMed ID: 19667257
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluating the risks and benefits of phase II and III cancer clinical trials: a look at Institutional Review Board members in the Netherlands.
    Van Luijn HE; Musschenga AW; Keus RB; Aaronson NK
    IRB; 2007; 29(1):13-8. PubMed ID: 17855839
    [No Abstract]   [Full Text] [Related]  

  • 10. Quality of life in clinical cancer trials: experience and perspective of the European Organization for Research and Treatment of Cancer.
    Kiebert GM; Kaasa S
    J Natl Cancer Inst Monogr; 1996; (20):91-5. PubMed ID: 8750477
    [No Abstract]   [Full Text] [Related]  

  • 11. Importance of registering clinical trials.
    Tator CH
    J Am Coll Surg; 2006 Jul; 203(1):140-1; author reply 141. PubMed ID: 16798506
    [No Abstract]   [Full Text] [Related]  

  • 12. Elderly cancer patients in clinical trials: conclusions of the UKCCCR Working Group.
    Eur J Surg Oncol; 1998 Oct; 24(5):422. PubMed ID: 9800972
    [No Abstract]   [Full Text] [Related]  

  • 13. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The national cancer data base: what does it mean to the community surgeon?
    Bland KI; Menck HR; Partridge EE; Fremgen A; Scott-Conner CE; Hundahl S; Winchester DP; Morrow M
    J Surg Oncol; 2000 Apr; 73(4):189-91. PubMed ID: 10797330
    [No Abstract]   [Full Text] [Related]  

  • 15. Survey of public information about ongoing clinical trials funded by industry: evaluation of completeness and accessibility.
    Manheimer E; Anderson D
    BMJ; 2002 Sep; 325(7363):528-31. PubMed ID: 12217994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Report on controlled therapeutic trials in progress registered by the Information Office of the Committee on Controlled Therapeutic Trials of the UICC.
    Flamant R
    Int J Cancer; 1969 Nov; 4(6):891-3. PubMed ID: 4908565
    [No Abstract]   [Full Text] [Related]  

  • 17. The Di Bella multitherapy trial. Criticism ignores standard methodology of cancer treatments.
    Raschetti R; Greco D; Menniti-Ippolito F; Spila-Alegiani S; Benagiano G; Bruzzi P
    BMJ; 1999 Apr; 318(7190):1074. PubMed ID: 10336293
    [No Abstract]   [Full Text] [Related]  

  • 18. A strategy for collecting pharmacoeconomic data during phase II/III clinical trials.
    Mauskopf J; Schulman K; Bell L; Glick H
    Pharmacoeconomics; 1996 Mar; 9(3):264-77. PubMed ID: 10160101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protocol information provides opportunity for patient safety and quality improvement.
    George TJ; Leather H
    J Clin Oncol; 2011 Jun; 29(18):e563. PubMed ID: 21576645
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical trials referral resource. Current phase II and phase III clinical trials for pancreatic cancer.
    Mooney MM; Schoenfeldt M
    Oncology (Williston Park); 2004 Jul; 18(8):1008, 1013-4, 1016. PubMed ID: 15328895
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.